Drugs as molecules that bind to receptors or enzymes, the action of agonists and antagonists, the role of functional groups in binding, structure-activity relationships, and how these ideas guide the design of medicines.

What this key area is asking

The SQA wants you to describe drugs as molecules that bind to receptors or enzymes, to explain the action of agonists and antagonists, to explain how functional groups and shape govern binding, and to use structure-activity relationships in drug design. The agonist-versus-antagonist distinction and the role of complementary shape and functional groups are reliable exam earners.

Drugs, receptors and enzymes

The body's own active compounds bind to the same sites; a drug works by either mimicking or blocking that natural binding.

Agonists and antagonists

For example, a painkiller may act as an agonist at receptors that dull pain signals, while a beta-blocker acts as an antagonist that blocks receptors involved in raising heart rate.

Functional groups and binding

The strength and specificity of binding depend on the functional groups the drug carries. Groups such as hydroxyl, amino and carboxyl can form hydrogen bonds or ionic attractions with matching groups in the binding site, while the overall shape must fit. Because the binding site is itself chiral, the two enantiomers of a drug often bind differently, which is why single-enantiomer drugs are often required.

Structure-activity relationships in drug design

Examples in context

Pharmaceutical chemistry connects organic synthesis to medicine. Aspirin, made by esterifying salicylic acid, inhibits an enzyme that produces pain and inflammation signals, an example of an enzyme-targeting drug. Antihistamines act as antagonists, blocking the histamine receptors that cause allergic symptoms, while salbutamol acts as an agonist at receptors that relax airway muscles in asthma. The role of shape and chirality is dramatic: many drugs are sold as single enantiomers because only one shape fits the receptor well, and getting the stereochemistry wrong can reduce potency or cause harm. Designing a route to make these molecules efficiently, and proving their structure by spectroscopy, ties this key area back to synthesis and to the experimental determination of structure.

Try this

Q1. Explain what is meant by an agonist. [1 mark]

• Cue. A drug that binds to a receptor and produces the same response as the body's natural active compound.

Q2. Explain what is meant by an antagonist. [1 mark]

• Cue. A drug that binds to a receptor but blocks the response, occupying the site without triggering it.

Q3. State why the shape of a drug molecule is important. [1 mark]

• Cue. It must be complementary to the binding site so the drug can fit and bind.